Two-component pharmaceutical composition for the treatment of pain

Inactive Publication Date: 2006-12-14
BRIDGE THERAPEUTICS INC
View PDF29 Cites 36 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The present invention is directed to a pharmaceutical composition that includes a combination of a non-steroidal anti-inflammatory drug such as piroxicam and an opioid analgesic such as buprenorphine in a pharmaceutical dosage unit that provides safe and effective pain management with the added benefit that side effects such as gastrointestinal tract damage and withdrawal as a result of physical dependence and/or ad

Problems solved by technology

Furthermore, chronic pain has been said to be the most costly health problem in America.
Thus, pain management has been identified as one of the most difficult challenges for the health care industry.
NSAIDs are well absorbed following oral administration but there is a high potential for adverse side-effects such as ulcerations, abdominal pain, cramping, nausea, gastritis, kidney disease, angiodema, pancreatitis, and even serious gastrointestinal bleeding and liver toxicity at the upper limits of their effective dose ranges.
Thus, the ability to use higher dosages of NSAIDs is generally limi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Two-component pharmaceutical composition for the treatment of pain
  • Two-component pharmaceutical composition for the treatment of pain

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

[0037] Patients taking 15-80 mg / day of hydrocodone or 40-320 mg / day of oxycontin were switched to a pharmaceutical dosage unit including 2.5 mg piroxicam and 2 mg buprenorphine in a sublingual tablet. The sublingual tablets were administered to each patient twice daily. The patients perceived pain was measured using a visual analog scale (VAS).

[0038] Patients formerly taking 15-80 mg / day of hydrocodone experienced a 21% decrease in perceived pain scores after conversion. The perceived pain scores also remained stable when ½ dose reduction was attempted after a 22 day stabilization phase.

[0039] Patients that had been taking 40-320 mg / day of oxycontin experienced a 27% reduction in perceived pain 72 hours after conversion. No withdrawal or parasympathetic symptoms were noted in the oxycontin patients. The perceived pain scores remained stable when dose reduction was attempted after a 40-day stabilization phase.

[0040] The patients also generally reported feelings of being ...

Example

Example 2

[0041] Patients taking 20-140 mg / day of methadone were also switched to a pharmaceutical dosage unit including 2.5 mg piroxicam and 2 mg buprenorphine in a sublingual tablet. These patients took an average of 6 days to convert before withdrawal was completely eliminated.

[0042] Patients taking 20-50 mg / day of methadone converted without ill effects, but did not take methadone the first day.

[0043] Patients taking 50-140 mg / day of methadone were first titrated down with Ultram (2-3 tablets every 4 hrs) for four days. Following this period, patients were given injections containing 0.03 mg buprenorphine and 60 mg torodol to see if further time was needed before the sublingual tablets containing buprenorphine and piroxicam could be started without risk of precipitating withdrawal. Significant withdrawal was observed in 18% of the patients on the first day the sublingual tablets were administered. Stomach tightness, nausea, and restless legs were the most common complaints fro...

Example

Example 3

[0045] Patients that had been taking piroxicam were also switched to a pharmaceutical dosage unit including 2.5 mg piroxicam and 2 mg buprenorphine in a sublingual tablet. The patients reported a 50% reduction in GI upset compared to when they were taking piroxicam orally.

[0046] The particular embodiments disclosed above are illustrative only, as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimen.

Description

[0001] The invention relates generally to a pharmaceutical dosage unit having a therapeutically effective amount of a non-steroidal anti-inflammatory drug in combination with a therapeutically effective amount of an opioid analgesic that can be used for the treatment of pain with reduced side effects such as opioid withdrawal and gastrointestinal irritation and damage. More particularly, the pharmaceutical dosage unit includes piroxicam in combination with buprenorphine for sublingual administration. BACKGROUND OF THE INVENTION [0002] Pain is prevalent. It is estimated that more than 50 million Americans live with chronic pain caused by various diseases or disorders, and each year nearly 25 million people suffer with acute pain as a result of injury or surgery. Furthermore, chronic pain has been said to be the most costly health problem in America. Estimated annual costs, including direct medical expenses, lost income, lost productivity, compensation payments, and legal charges are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/485A61K31/192
CPCA61K31/192A61K31/485A61K45/06A61K31/5415A61K2300/00A61P29/00
Inventor KELLY, ALTON SAMUEL IISULLIVAN, JAMES GREGORY
Owner BRIDGE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap